14.44
-0.23 (-1.57%)
| Previous Close | 14.67 |
| Open | 14.67 |
| Volume | 594,046 |
| Avg. Volume (3M) | 1,001,491 |
| Market Cap | 1,176,643,328 |
| Price / Sales | 3.25 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -121,488.89% |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 3.44% |
| Current Ratio (MRQ) | 15.43 |
| Operating Cash Flow (TTM) | -232.32 M |
| Levered Free Cash Flow (TTM) | -136.82 M |
| Return on Assets (TTM) | -30.32% |
| Return on Equity (TTM) | -48.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Viridian Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.0 |
| Average | 2.50 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 114.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kynam Capital Management, Lp | 31 Dec 2024 | 3,326,262 |
| Commodore Capital Lp | 31 Dec 2024 | 2,400,000 |
| Novo Holdings A/S | 31 Dec 2024 | 2,250,000 |
| Maverick Capital Ltd | 31 Dec 2024 | 2,053,906 |
| Paradigm Biocapital Advisors Lp | 31 Dec 2024 | 1,820,079 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (RBC Capital, 211.63%) | Buy |
| Median | 36.00 (149.31%) | |
| Low | 27.00 (Goldman Sachs, 86.98%) | Buy |
| Average | 36.00 (149.31%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 2.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 07 May 2025 | 27.00 (86.98%) | Buy | 0.000 |
| JMP Securities | 07 May 2025 | 38.00 (163.16%) | Buy | 0.000 |
| Needham | 07 May 2025 | 36.00 (149.31%) | Buy | 0.000 |
| RBC Capital | 07 May 2025 | 45.00 (211.63%) | Buy | 0.000 |
| HC Wainwright & Co. | 23 Apr 2025 | 34.00 (135.46%) | Buy | 13.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 May 2025 | Announcement | Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) |
| 06 May 2025 | Announcement | Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results |
| 02 May 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Apr 2025 | Announcement | Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors |
| 10 Mar 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 27 Feb 2025 | Announcement | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |